Premature thelarche

Last updated
Premature thelarche
Precocious thelarche.JPG
Infant with premature thelarche
Specialty Gynecology, endocrinology

Premature thelarche (PT) is a medical condition, characterised by isolated breast development in female infants. It occurs in females younger than 8 years, with the highest occurrence before the age of 2. PT is rare, occurring in 2.2-4.7% of females aged 0 to 2 years old. [1] The exact cause of the condition is still unknown, but it has been linked to a variety of genetic, dietary and physiological factors. [2]

Contents

PT is a form of Incomplete Precocious Puberty (IPP). IPP is the presence of a secondary sex characteristic in an infant, without a change in their sex hormone levels. Central Precocious Puberty (CPP) is a more severe condition than IPP. CPP is the presentation of secondary sex characteristics, with a change in sex hormones due to alteration of the hypothalamic-pituitary-gonadal (HPG) axis. [1] CPP is an aggressive endocrine disorder with harmful developmental consequences for the patient. At the presentation of PT, diagnostics are used to ensure it is not early stage CPP. CPP can be differentiated from PT through biochemical testing, ultrasounds and ongoing observation. [3] There is no treatment for PT but regular observation is important to ensure it does not progress to CPP. CPP diagnosis is important as treatment is necessary. [1]

Symptoms and signs

Premature thelarche is breast hypertrophy before puberty. This form of hypertrophy is an increase in breast tissue. PT occurs in pre-pubescent females, under the age of 8, having a peak occurrence in the first two years of life. [4] The breast development is usually bi-lateral: both breasts show development. In some cases development may be unilateral: one breast develops.[ citation needed ]

Patterns of PT

There are four patterns of PT development. Most patients have hypertrophy followed by complete loss of the excess breast tissue (51% of cases) or loss of most excess tissue, but some remains until puberty (36% of cases). Less commonly patients have ongoing patterns of thelarche: 9.7% suffer from a cyclic pattern where the size of the breast tissue varies over time, and 3.2% experience continual increase in tissue size. [1]

Associated Symptoms

The main symptom of PT is enlarged breast tissue in infants. estrogen's role in PT, also leads to increased bone age and growth in some cases. [5] In PT these secondary symptoms are minimal: bone age only varies from actual age by a few months and growth velocity only slightly varies from the norm. Diagnostic tests will distinguish these PT secondary symptoms from the more severe bone aging and growth occurring in early CPP. [3]

Pathophysiology

The direct pathophysiology behind PT is still unknown, but there are many postulated causes. [2]

Estrogen

PT is linked to increased sensitivity of the breast tissue to estradiol, an estrogen derivative, in certain prepubertal individuals. [1] Sporadic estrogen or estradiol production in the adrenal glands, follicles or ovarian cysts is also linked to the condition. [2] [6]

Follicle stimulating hormone

Follicle Stimulating Hormone (FSH) is secreted from the anterior pituitary. FSH plays a key role in development, growth and puberty, thus it is suspected to play a role in PT. Gondotropin-releasing hormone (GnRH) stimulation testing in some patients with PT has shown a dominant response from FSH. This response is linked to active mutations in the FSH receptor and Gs-a subunit in PT. Genetic investigation indicated these mutations only account for few cases of premature PT. [2] [7] PT may also be caused by transient partial activation of the HPG axis. Partial activation would release a surplus of FSH from the anterior pituitary without further disruption of the HPG axis. [6]

Other causes

The consumption or exposure to certain endocrine disrupters have also been linked to PT. [2]

CPP and PT

PT is the benign growth of breasts in infants, while CPP is a condition that involves the frequent activation of the HPG axis in patients. PT does not require treatment, as the condition is limited to enlarged breast tissue that usually subsides with time. CPP is associated with a wider range of symptoms including thelarche, pubic hair growth, accelerated bone aging, increased growth velocity and early epiphyseal growth. If an individual is affected with CPP they will need to begin treatment immediately. CPP is treated with lutenizing hormone (LH) releasing hormone agonists. PT can impact growth velocity and bone age slightly, but CPP affects these characteristics to the point of detriment to the adult stature. [1] Patients with suspected PT must undergo diagnostic testing to ensure it isn’t CPP or exaggerated thelarche, the intermediate stage before CPP. [3]

Notable hormone differences occur between CPP and PT patients, so studying these hormone levels is the main biochemical diagnostic used in CPP. [4] Individuals with CPP usually have a higher basal LH levels and LH:FSH ratios. [1] [4]

Few PT patients, 9 to 14%, are predicted to develop CPP. [1] [4] Observation allows clinicians to identify the presentation of CPP indicative symptoms in PT patients. No diagnostics tests can indicate if a PT patient is at risk of developing CPP. [4]

Diagnosis

Premature thelarche does not require treatment. In PT, breast hypertrophy will usually stop completely and patients will experience regression of the breast tissue over 3 to 60 months. Less commonly, patients may remain with residual breast tissue or continue through cycles of breast hypertrophy and regression until puberty. [1]

Diagnostics are utilised in individuals with PT, especially at the presentation of other secondary sex characteristics. Diagnostics aim to ensure PT patients are not suffering from CPP. [1]

Pelvic Ultrasounds

Pelvic ultrasounds are important in diagnosing CPP. [3] Patients with CPP have an increased ovary and uterus size. The ovary and uterus volume of CPP patients is similar to that of females undergoing puberty. [1] The pelvis ultrasound is problematic as a diagnostic, as there is not a specific cut-off for the uterine and ovary volumes that indicate the patient has CPP. Patients with PT should have a uterine and ovarian volume within the normal range for their age. Pelvic ultrasounds are a desirable diagnostic as they are non-invasive and easy to continually review. The pelvic ultrasound should be paired with biochemical tests to determine the presence of CPP. [3]

Biochemical tests

Biochemical tests study the hormone levels in patients. CPP patients have elevated LH levels and peak LH:FSH ratios when compared to PT patients. It is hard to use LH as a diagnostic for CPP, as the LH assay has varying sensitivity and specificity. [1] The GnRH stimulation test is the main diagnostic biochemical test used to distinguish PT from CPP. [3] The GnRH test demonstrates the pituitary responsiveness to GnRH. GnRH stimulates the release of LH and FSH from the anterior pituitary. The peak LH:FSH ratio in CPP patients is similar to the ratio of pubertal females. Females with PT demonstrated a LH:FSH ratio lower than pubertal females. [8] The disadvantages of the GnRH stimulation test is it takes a long time to perform and requires multiple collections from the patient, making the process time consuming and inconvenient. The test is highly specific but has low sensitivity as the LH hormone response is usually observed in later stages of CPP. [3] There are also overlaps in the expected value in the GnRH test results of individuals with CPP and PT. [1]

Combined diagnostic approach

The diagnostic inconsistency in CPP means that a combination of all of pelvic ultrasounds and biochemical tests should be paired with observation, to ensure PT doesn’t progress to CPP. [1]

Research

Exposure to environmental agents

Natural commodities like fennel, lavender and tea tree oils have been linked to PT. Lavender and tea tree oil have weak estrogenic activities. These estrogenic properties may cause an imbalance in endocrine signalling pathways, leading to PT in regular users of these products. [1] Fennel tea has been studied as an endocrine disrupter linked to PT. Fennel seed oil contains anethole a compound with estrogenic effects. The tea contains fennel seed oil and regular use results in increased estradiol levels in the infant. Infants with fennel tea related PT, were given the tea as a homeopathic remedy for restlessness. The tea was consumed for at least four months before the presentation of PT symptoms. PT resulting from fennel tea subsides approximately six months after stopping the use of fennel tea. [9]

Leptin

Leptin is an adipocyte hormone that has important implications of puberty and sex hormone secretion. Increased leptin has been linked to estrogen and estradiol secretion. Leptin has key roles in maintaining age appropriate body composition and desired weight. Leptin receptors are also found in mammary epithelial cells and leptin has been observed as a growth factor in breast tissue. Increased leptin levels have been observed in some cases of PT. The increase in leptin levels cause increased estradiol levels and development of breast tissue. [6]

GNAS1 gene mutation

The form of PT with fluctuating hypertrophy in patients has been linked to activating mutations in the GNAS1 gene. This mutation accounts for a small number of cases of PT. [5] [7]

See also

Related Research Articles

Amenorrhea is the absence of a menstrual period in a female who has reached reproductive age. Physiological states of amenorrhoea are seen, most commonly, during pregnancy and lactation (breastfeeding). Outside the reproductive years, there is absence of menses during childhood and after menopause.

<span class="mw-page-title-main">Luteinizing hormone</span> Gonadotropin secreted by the adenohypophysis

Luteinizing hormone is a hormone produced by gonadotropic cells in the anterior pituitary gland. The production of LH is regulated by gonadotropin-releasing hormone (GnRH) from the hypothalamus. In females, an acute rise of LH known as an LH surge, triggers ovulation and development of the corpus luteum. In males, where LH had also been called interstitial cell–stimulating hormone (ICSH), it stimulates Leydig cell production of testosterone. It acts synergistically with follicle-stimulating hormone (FSH).

<span class="mw-page-title-main">Anterior pituitary</span> Anterior lobe of the pituitary gland

A major organ of the endocrine system, the anterior pituitary is the glandular, anterior lobe that together with the posterior lobe makes up the pituitary gland (hypophysis). The anterior pituitary regulates several physiological processes, including stress, growth, reproduction, and lactation. Proper functioning of the anterior pituitary and of the organs it regulates can often be ascertained via blood tests that measure hormone levels.

<span class="mw-page-title-main">Gonadotropin-releasing hormone</span> Mammalian protein found in Homo sapiens

Gonadotropin-releasing hormone (GnRH) is a releasing hormone responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. GnRH is a tropic peptide hormone synthesized and released from GnRH neurons within the hypothalamus. The peptide belongs to gonadotropin-releasing hormone family. It constitutes the initial step in the hypothalamic–pituitary–gonadal axis.

In medicine, precocious puberty is puberty occurring at an unusually early age. In most cases, the process is normal in every aspect except the unusually early age and simply represents a variation of normal development. In a minority of children with precocious puberty, the early development is triggered by a disease such as a tumor or injury of the brain. Even when there is no disease, unusually early puberty can have adverse effects on social behavior and psychological development, can reduce adult height potential, and may shift some lifelong health risks. Central precocious puberty can be treated by suppressing the pituitary hormones that induce sex steroid production. The opposite condition is delayed puberty.

Delayed puberty is when a person lacks or has incomplete development of specific sexual characteristics past the usual age of onset of puberty. The person may have no physical or hormonal signs that puberty has begun. In the United States, girls are considered to have delayed puberty if they lack breast development by age 13 or have not started menstruating by age 15. Boys are considered to have delayed puberty if they lack enlargement of the testicles by age 14. Delayed puberty affects about 2% of adolescents.

Gonadotropins are glycoprotein hormones secreted by gonadotropic cells of the anterior pituitary of vertebrates. This family includes the mammalian hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH), the placental/chorionic gonadotropins, human chorionic gonadotropin (hCG) and equine chorionic gonadotropin (eCG), as well as at least two forms of fish gonadotropins. These hormones are central to the complex endocrine system that regulates normal growth, sexual development, and reproductive function. LH and FSH are secreted by the anterior pituitary gland, while hCG and eCG are secreted by the placenta in pregnant humans and mares, respectively. The gonadotropins act on the gonads, controlling gamete and sex hormone production.

Gonadarche refers to the earliest gonadal changes of puberty. In response to pituitary gonadotropins, the ovaries in females and the testes in males begin to grow and increase the production of the sex steroids, especially estradiol and testosterone. The ovary and testis have receptors, follicle cells and leydig cells, respectively, where gonadotropins bind to stimulate the maturation of the gonads and secretion of estrogen and testosterone. Certain disorders can result in changes to timing or nature of these processes.

<span class="mw-page-title-main">Thelarche</span> Beginning of development of the breasts in the female

Thelarche, also known as breast budding, is the onset of secondary breast development, often representing the beginning of pubertal development. It is the stage at which male and female breasts differentiate due to variance in hormone levels; however, some males have a condition in which they develop breasts, termed gynecomastia. Thelarche typically occurs between the ages of 8 and 13 years with significant variation between individuals. However, the initial growth of breast tissue occurs during fetal development.

<span class="mw-page-title-main">Hypothalamic–pituitary–gonadal axis</span> Concept of regarding the hypothalamus, pituitary gland and gonadal glands as a single entity

The hypothalamic–pituitary–gonadal axis refers to the hypothalamus, pituitary gland, and gonadal glands as if these individual endocrine glands were a single entity. Because these glands often act in concert, physiologists and endocrinologists find it convenient and descriptive to speak of them as a single system.

<span class="mw-page-title-main">Gonadotropin-releasing hormone antagonist</span> Class of medications

Gonadotropin-releasing hormone antagonists are a class of medications that antagonize the gonadotropin-releasing hormone receptor and thus the action of gonadotropin-releasing hormone (GnRH). They are used in the treatment of prostate cancer, endometriosis, uterine fibroids, female infertility in assisted reproduction, and for other indications.

<span class="mw-page-title-main">Histrelin</span> Chemical compound

Histrelin acetate, sold under the brand names Vantas and Supprelin LA among others, is a nonapeptide analogue of gonadotropin-releasing hormone (GnRH) with added potency. When present in the bloodstream, it acts on particular cells of the pituitary gland called gonadotropes. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.

Functional hypothalamic amenorrhea (FHA) is a form of amenorrhea and chronic anovulation and is one of the most common types of secondary amenorrhea. It is classified as hypogonadotropic hypogonadism. It was previously known as "juvenile hypothalamosis syndrome," prior to the discovery that sexually mature females are equally affected. FHA has multiple risk factors, with links to stress-related, weight-related, and exercise-related factors. FHA is caused by stress-induced suppression of the hypothalamic-pituitary-ovarian (HPO) axis, which results in inhibition of gonadotropin-releasing hormone (GnRH) secretion, and gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Severe and potentially prolonged hypoestrogenism is perhaps the most dangerous hormonal pathology associated with the disease, because consequences of this disturbance can influence bone health, cardiovascular health, mental health, and metabolic functioning in both the short and long-term. Because many of the symptoms overlap with those of organic hypothalamic, pituitary, or gonadal disease and therefore must be ruled out, FHA is a diagnosis of exclusion; "functional" is used to indicate a behavioral cause, in which no anatomical or organic disease is identified, and is reversible with correction of the underlying cause. Diagnostic workup includes a detailed history and physical, laboratory studies, such as a pregnancy test, and serum levels of FSH and LH, prolactin, and thyroid-stimulating hormone (TSH), and imaging. Additional tests may be indicated in order to distinguish FHA from organic hypothalamic or pituitary disorders. Patients present with a broad range of symptoms related to severe hypoestrogenism as well as hypercortisolemia, low serum insulin levels, low serum insulin-like growth factor 1 (IGF-1), and low total triiodothyronine (T3). Treatment is primarily managing the primary cause of the FHA with behavioral modifications. While hormonal-based therapies are potential treatment to restore menses, weight gain and behavioral modifications can have an even more potent impact on reversing neuroendocrine abnormalities, preventing further bone loss, and re-establishing menses, making this the recommended line of treatment. If this fails to work, secondary treatment is aimed at treating the effects of hypoestrogenism, hypercortisolism, and hypothyroidism.

Hypergonadism is a condition where there is a hyperfunction of the gonads. It can manifest as precocious puberty, and is caused by abnormally high levels of testosterone or estrogen, crucial hormones for sexual development. In some cases, it may be caused by a tumor, which can be malignant, but is more commonly benign. Anabolic steroids may also be a major cause of high androgen and estrogen functional activity. Other possible causes include head injuries and brain inflammatory diseases. Hypergonadism may contribute to symptoms such as precocious puberty and abnormal facial hair growth in females.

Puberty is the process of physical changes through which a child's body matures into an adult body capable of sexual reproduction. It is initiated by hormonal signals from the brain to the gonads: the ovaries in a female, the testicles in a male. In response to the signals, the gonads produce hormones that stimulate libido and the growth, function, and transformation of the brain, bones, muscle, blood, skin, hair, breasts, and sex organs. Physical growth—height and weight—accelerates in the first half of puberty and is completed when an adult body has been developed. Before puberty, the external sex organs, known as primary sexual characteristics, are sex characteristics that distinguish males and females. Puberty leads to sexual dimorphism through the development of the secondary sex characteristics, which further distinguish the sexes.

Hypergonadotropic hypogonadism (HH), also known as primary or peripheral/gonadal hypogonadism or primary gonadal failure, is a condition which is characterized by hypogonadism which is due to an impaired response of the gonads to the gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and in turn a lack of sex steroid production. As compensation and the lack of negative feedback, gonadotropin levels are elevated. Individuals with HH have an intact and functioning hypothalamus and pituitary glands so they are still able to produce FSH and LH. HH may present as either congenital or acquired, but the majority of cases are of the former nature. HH can be treated with hormone replacement therapy.

Gonadotropin-releasing hormone (GnRH) insensitivity also known as Isolated gonadotropin-releasing hormone (GnRH)deficiency (IGD) is a rare autosomal recessive genetic and endocrine syndrome which is characterized by inactivating mutations of the gonadotropin-releasing hormone receptor (GnRHR) and thus an insensitivity of the receptor to gonadotropin-releasing hormone (GnRH), resulting in a partial or complete loss of the ability of the gonads to synthesize the sex hormones. The condition manifests itself as isolated hypogonadotropic hypogonadism (IHH), presenting with symptoms such as delayed, reduced, or absent puberty, low or complete lack of libido, and infertility, and is the predominant cause of IHH when it does not present alongside anosmia.

Hypogonadotropic hypogonadism (HH), is due to problems with either the hypothalamus or pituitary gland affecting the hypothalamic-pituitary-gonadal axis. Hypothalamic disorders result from a deficiency in the release of gonadotropic releasing hormone (GnRH), while pituitary gland disorders are due to a deficiency in the release of gonadotropins from the anterior pituitary. GnRH is the central regulator in reproductive function and sexual development via the HPG axis. GnRH is released by GnRH neurons, which are hypothalamic neuroendocrine cells, into the hypophyseal portal system acting on gonadotrophs in the anterior pituitary. The release of gonadotropins, LH and FSH, act on the gonads for the development and maintenance of proper adult reproductive physiology. LH acts on Leydig cells in the male testes and theca cells in the female. FSH acts on Sertoli cells in the male and follicular cells in the female. Combined this causes the secretion of gonadal sex steroids and the initiation of folliculogenesis and spermatogenesis. The production of sex steroids forms a negative feedback loop acting on both the anterior pituitary and hypothalamus causing a pulsatile secretion of GnRH. GnRH neurons lack sex steroid receptors and mediators such as kisspeptin stimulate GnRH neurons for pulsatile secretion of GnRH.

Gonadotropin surge-attenuating factor (GnSAF) is a nonsteroidal ovarian hormone produced by the granulosa cells of small antral ovarian follicles in females. GnSAF is involved in regulating the secretion of luteinizing hormone (LH) from the anterior pituitary and the ovarian cycle. During the early to mid-follicular phase of the ovarian cycle, GnSAF acts on the anterior pituitary to attenuate LH release, limiting the secretion of LH to only basal levels. At the transition between follicular and luteal phase, GnSAF bioactivity declines sufficiently to permit LH secretion above basal levels, resulting in the mid-cycle LH surge that initiates ovulation. In normally ovulating women, the LH surge only occurs when the oocyte is mature and ready for extrusion. GnSAF bioactivity is responsible for the synchronised, biphasic nature of LH secretion.

Kisspeptin, neurokinin B, and dynorphin (KNDy) neurons are neurons in the hypothalamus of the brain that are central to the hormonal control of reproduction.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Khokar A, Mojia A (2018). "Premature Thelarche". Pediatric Annals. 47 (1): 12–15.
  2. 1 2 3 4 5 Rezkalla J, Von Wald T, Hansen KA (June 2017). "Premature Thelarche and the PURA Syndrome". Obstetrics and Gynecology. 129 (6): 1037–1039. doi:10.1097/AOG.0000000000002047. PMID   28486374.
  3. 1 2 3 4 5 6 7 Lee SH, Joo EY, Lee JE, Jun YH, Kim MY (January 2016). "The Diagnostic Value of Pelvic Ultrasound in Girls with Central Precocious Puberty". Chonnam Medical Journal. 52 (1): 70–4. doi:10.4068/cmj.2016.52.1.70. PMC   4742613 . PMID   26866003.
  4. 1 2 3 4 5 Sømod ME, Vestergaard ET, Kristensen K, Birkebæk NH (2016-02-22). "Increasing incidence of premature thelarche in the Central Region of Denmark - Challenges in differentiating girls less than 7 years of age with premature thelarche from girls with precocious puberty in real-life practice". International Journal of Pediatric Endocrinology. 2016 (1): 4. doi: 10.1186/s13633-016-0022-x . PMC   4763410 . PMID   26909102.
  5. 1 2 Codner E, Román R (March 2008). "Premature thelarche from phenotype to genotype". Pediatric Endocrinology Reviews. 5 (3): 760–5. PMID   18367996.
  6. 1 2 3 Dundar B, Pirgon O, Sangun O, Doguc DK (August 2013). "Elevated leptin levels in nonobese girls with premature thelarche". Journal of Investigative Medicine. 61 (6): 984–8. doi:10.2310/JIM.0b013e31829cbe20. PMID   23838698. S2CID   22270791.
  7. 1 2 Román R, Johnson MC, Codner E, Boric MA, áVila A, Cassorla F (August 2004). "Activating GNAS1 gene mutations in patients with premature thelarche". The Journal of Pediatrics. 145 (2): 218–22. doi:10.1016/j.jpeds.2004.05.025. PMID   15289771.
  8. ↑ Zevenhuijzen H, Kelnar CJ, Crofton PM (2004). "Diagnostic utility of a low-dose gonadotropin-releasing hormone test in the context of puberty disorders". Hormone Research. 62 (4): 168–76. doi:10.1159/000080324. PMID   15331852. S2CID   23120189.
  9. ↑ Okdemir D, Hatipoglu N, Kurtoglu S, Akın L, Kendirci M (January 2014). "Premature thelarche related to fennel tea consumption?". Journal of Pediatric Endocrinology & Metabolism. 27 (1–2): 175–9. doi:10.1515/jpem-2013-0308. PMID   24030028. S2CID   20871881.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.